Chad Messer
Stock Analyst at Lake Street
(0.68)
# 4,102
Out of 5,141 analysts
30
Total ratings
23.33%
Success rate
-18.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chad Messer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMNM Immunome | Maintains: Buy | $22 → $32 | $21.50 | +48.84% | 2 | Dec 16, 2025 | |
| OSTX OS Therapies | Maintains: Buy | $18 → $17 | $1.18 | +1,340.68% | 2 | Nov 18, 2025 | |
| GNLX Genelux | Initiates: Buy | $16 | $2.64 | +506.06% | 1 | Oct 21, 2025 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $106 | $55.41 | +91.30% | 1 | Sep 23, 2025 | |
| BOLT Bolt Biotherapeutics | Maintains: Buy | $4 → $75 | $5.05 | +1,385.15% | 2 | Aug 15, 2025 | |
| ONCY Oncolytics Biotech | Initiates: Buy | $7 | $0.96 | +626.14% | 1 | Aug 13, 2025 | |
| COYA Coya Therapeutics | Initiates: Buy | $16 | $4.61 | +247.07% | 1 | Jul 9, 2025 | |
| LTRN Lantern Pharma | Initiates: Buy | $25 | $2.61 | +857.85% | 1 | Apr 2, 2025 | |
| ESPR Esperion Therapeutics | Maintains: Strong Buy | $134 → $114 | $3.48 | +3,175.86% | 3 | Aug 3, 2021 | |
| CELC Celcuity | Initiates: Buy | $50 | $104.79 | -52.29% | 1 | Jul 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $48 | $67.94 | -29.35% | 2 | Jul 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $30 | $43.63 | -31.24% | 3 | Jun 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $72.86 | -31.38% | 1 | Jun 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $29 | $7.03 | +312.52% | 2 | May 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $0.42 | +2,259.05% | 1 | Apr 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $95 → $86 | $83.15 | +3.43% | 2 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $44 | $15.78 | +178.83% | 2 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $182 → $166 | $18.88 | +779.24% | 1 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $18 | $1.18 | +1,425.42% | 1 | May 5, 2020 |
Immunome
Dec 16, 2025
Maintains: Buy
Price Target: $22 → $32
Current: $21.50
Upside: +48.84%
OS Therapies
Nov 18, 2025
Maintains: Buy
Price Target: $18 → $17
Current: $1.18
Upside: +1,340.68%
Genelux
Oct 21, 2025
Initiates: Buy
Price Target: $16
Current: $2.64
Upside: +506.06%
Monopar Therapeutics
Sep 23, 2025
Initiates: Buy
Price Target: $106
Current: $55.41
Upside: +91.30%
Bolt Biotherapeutics
Aug 15, 2025
Maintains: Buy
Price Target: $4 → $75
Current: $5.05
Upside: +1,385.15%
Oncolytics Biotech
Aug 13, 2025
Initiates: Buy
Price Target: $7
Current: $0.96
Upside: +626.14%
Coya Therapeutics
Jul 9, 2025
Initiates: Buy
Price Target: $16
Current: $4.61
Upside: +247.07%
Lantern Pharma
Apr 2, 2025
Initiates: Buy
Price Target: $25
Current: $2.61
Upside: +857.85%
Esperion Therapeutics
Aug 3, 2021
Maintains: Strong Buy
Price Target: $134 → $114
Current: $3.48
Upside: +3,175.86%
Celcuity
Jul 27, 2021
Initiates: Buy
Price Target: $50
Current: $104.79
Upside: -52.29%
Jul 19, 2021
Maintains: Buy
Price Target: $33 → $48
Current: $67.94
Upside: -29.35%
Jun 28, 2021
Maintains: Buy
Price Target: $33 → $30
Current: $43.63
Upside: -31.24%
Jun 17, 2021
Initiates: Buy
Price Target: $50
Current: $72.86
Upside: -31.38%
May 14, 2021
Maintains: Buy
Price Target: $31 → $29
Current: $7.03
Upside: +312.52%
Apr 5, 2021
Initiates: Buy
Price Target: $10
Current: $0.42
Upside: +2,259.05%
Mar 23, 2021
Maintains: Buy
Price Target: $95 → $86
Current: $83.15
Upside: +3.43%
Jan 8, 2021
Maintains: Buy
Price Target: $35 → $44
Current: $15.78
Upside: +178.83%
Jan 8, 2021
Maintains: Buy
Price Target: $182 → $166
Current: $18.88
Upside: +779.24%
May 5, 2020
Maintains: Buy
Price Target: $15 → $18
Current: $1.18
Upside: +1,425.42%